These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 10467379)

  • 1. Use of composite scores in the quantification of deterioration in multiple sclerosis.
    Lienert C; Lechner-Scott J; Schött D; Constantinescu C; Kappos L
    Mult Scler; 1999 Aug; 5(4):220-2. PubMed ID: 10467379
    [No Abstract]   [Full Text] [Related]  

  • 2. Measuring handicap in multiple sclerosis.
    Thompson AJ
    Mult Scler; 1999 Aug; 5(4):260-2. PubMed ID: 10467385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.
    Sharrack B; Hughes RA
    Mult Scler; 1999 Aug; 5(4):223-33. PubMed ID: 10467380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome measures in multiple sclerosis clinical trials.
    Andersson PB; Goodkin DE
    Baillieres Clin Neurol; 1997 Oct; 6(3):409-28. PubMed ID: 10101581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome measures in multiple sclerosis.
    Amato MP; Portaccio E
    J Neurol Sci; 2007 Aug; 259(1-2):118-22. PubMed ID: 17376487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.
    Fischer JS; Rudick RA; Cutter GR; Reingold SC
    Mult Scler; 1999 Aug; 5(4):244-50. PubMed ID: 10467383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of impairment in MS: discussion of the scales in use.
    Amato MP; Ponziani G
    Mult Scler; 1999 Aug; 5(4):216-9. PubMed ID: 10467378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
    Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome measures in multiple sclerosis.
    Uitdehaag BM
    Handb Clin Neurol; 2014; 122():393-404. PubMed ID: 24507527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evoked potentials are of little use in the diagnosis or monitoring of MS: yes.
    McGuigan C
    Mult Scler; 2013 Dec; 19(14):1820-1. PubMed ID: 24277732
    [No Abstract]   [Full Text] [Related]  

  • 11. Reconsidering clinical outcomes in Multiple Sclerosis: relapses, impairment, disability and beyond.
    D'Souza M; Kappos L; Czaplinski A
    J Neurol Sci; 2008 Nov; 274(1-2):76-9. PubMed ID: 18817932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of follow-up and evolution of multiple sclerosis].
    Couvreur G
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1143-51. PubMed ID: 11787348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple sclerosis: assessment of disability and disability scales.
    Thompson AJ; Hobart JC
    J Neurol; 1998 Apr; 245(4):189-96. PubMed ID: 9591219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodology of clinical trials in multiple sclerosis.
    Mitsikostas DD
    Neurol Sci; 2006 Sep; 27 Suppl 5():S362-4. PubMed ID: 16998721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. European Database for MUltiple Sclerosis. EVALUation of the EDMUS system.
    Grimaud J; Amato MP; Confavreux C
    Mult Scler; 1999 Aug; 5(4):234-8. PubMed ID: 10467381
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical definition for multiple sclerosis treatment trials.
    Kurtzke JF
    Ann Neurol; 1994; 36 Suppl():S73-9. PubMed ID: 8017892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional clinical outcomes in multiple sclerosis: Current status and future prospects.
    Karabudak R; Dahdaleh M; Aljumah M; Alroughani R; Alsharoqi IA; AlTahan AM; Bohlega SA; Daif A; Deleu D; Amous A; Inshasi JS; Rieckmann P; Sahraian MA; Yamout BI
    Mult Scler Relat Disord; 2015 May; 4(3):192-201. PubMed ID: 26008936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multiple sclerosis: can therapy delay ongoing disability?].
    Havla J; Pellkofer HL; Hohlfeld R; Kümpfel T
    MMW Fortschr Med; 2011 Apr; 153(14):63-6. PubMed ID: 21966873
    [No Abstract]   [Full Text] [Related]  

  • 19. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
    Ontaneda D; LaRocca N; Coetzee T; Rudick R;
    Mult Scler; 2012 Aug; 18(8):1074-80. PubMed ID: 22740488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The symptom inventory disability-specific short forms for multiple sclerosis: construct validity, responsiveness, and interpretation.
    Schwartz CE; Bode RK; Quaranto BR; Vollmer T
    Arch Phys Med Rehabil; 2012 Sep; 93(9):1617-1628.e1. PubMed ID: 22580198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.